AtaCor Medical Raises $28M in Funding for Cardiac Rhythm Management System Development

AtaCor Medical's Series C Funding

Key Highlights:

• Series C Funding: Raised $28 million in Series C funding to support FDA submission and pilot study for its cardiac rhythm management system.
• Investors: Led by Arboretum Ventures, with participation from Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures, and BayMed Venture Partners.
• Proprietary Technology: AtaCor Medical's extravascular cardiac rhythm management system offers the benefits of traditional implantable cardiac defibrillation and temporary pacing without placing leads or devices in the heart or vascular system.

AtaCor Medical's Target Market

• Target Market: Cardiologists, cardiac surgeons, and healthcare providers specializing in cardiac rhythm management.
• Hospitals and Medical Centers: Facilities looking for innovative cardiac pacing and defibrillation solutions that minimize invasive procedures.
• Patient Care Organizations: Organizations focused on providing advanced cardiac care while minimizing risks and complications associated with traditional implantable devices.

What AtaCor Medical Needs to Buy

• Clinical Trial Support: Collaborating with research institutions and clinical trial service providers for conducting trials and gathering data on the efficacy and safety of their cardiac rhythm management system.
• Regulatory Compliance Services: Engaging with regulatory consultants and experts to navigate the FDA submission process and ensure compliance with relevant regulations.
• Manufacturing and Supply Chain Solutions: Partnering with manufacturers and suppliers to produce and distribute their cardiac rhythm management system.